- Home
- ZLAB vs EXEL Comparison
ZLAB vs EXEL Comparison
Compare ZLAB & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZLAB | EXEL |
|---|---|---|
| Founded | 2013 | 1994 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 11.7B |
| IPO Year | 2017 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ZLAB | EXEL |
|---|---|---|
| Price | $18.05 | $40.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 21 |
| Target Price | ★ $49.60 | $46.45 |
| AVG Volume (30 Days) | 569.8K | ★ 2.7M |
| Earning Date | 05-07-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.46 | ★ 57.95 |
| EPS | N/A | ★ 2.78 |
| Revenue | ★ $460,156,000.00 | $452,477,000.00 |
| Revenue This Year | $14.46 | $13.66 |
| Revenue Next Year | $29.47 | $13.39 |
| P/E Ratio | ★ N/A | $14.87 |
| Revenue Growth | ★ 15.33 | N/A |
| 52 Week Low | $15.96 | $32.38 |
| 52 Week High | $44.34 | $48.74 |
Technical Indicators
Market Signals| Indicator | ZLAB | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 42.20 | 42.12 |
| Support Level | $17.03 | $40.34 |
| Resistance Level | $19.71 | $41.75 |
| Average True Range (ATR) | 0.67 | 1.01 |
| MACD | -0.12 | -0.04 |
| Stochastic Oscillator | 37.26 | 37.31 |
Price Performance
Historical ComparisonAbout ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.